TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Toni K Choueiri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.